Cambrex has invested in an expansion of its flexible manufacturing facility in Sweden, which will increase the company’s flexible drug substance manufacturing capacity.
Cambrex has announced in a July 1, 2020 press release, that it has invested in an expansion of its flexible manufacturing facility in Sweden, which will increase the company’s flexible drug substance manufacturing capacity.
The expansion work will involve the modification of an existing four reactor configuration, installation of new holding tanks and a 4 m2 Hastelloy Rosemund filter, a conversion of a previously customer-dedicated manufacturing train, and will see the facility gain an additional production line at 6 m3 scale. The works should increase capacity of the facility by 25% and have already started, with an anticipated completion date in November 2020.
“We are seeing continued growth in commercial-scale API manufacturing, and an ongoing trend for customers favoring high-quality European and US partners, so we must ensure capacity is both flexible and available to be in a position to react quickly and effectively to customers’ changing requirements,” said Bjarne Sandberg, managing director, Cambrex Karlskoga, in the press release. “This investment, as with others made by Cambrex across our global network, is in line with the company strategy of ensuring that the assets we can offer customers allow for the most cost-effective and efficient manufacturing.”
Source: Cambrex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.